



#14
0300

PATENT
Attorney Docket No. A-70586-1/RFT/RMS/RMK
Dorsey File No. 468488-155

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MAYO et al.

Serial No.: 09/902,481

Filing Date: July 9, 2001

For: Novel Proteins with Integrin-like Activity

Examiner: UNKNOWN

Art Unit: 1653

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, BOX SEQUENCE, P.O. BOX 2327, Arlington, VA 22202 on:

Dated: Nov. 4, 2002

Signed: Marjorie Jost
Marjorie Jost

**RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES
AND AMENDMENT RE SEQUENCE LISTING**

Commissioner for Patents
U.S. Patent and Trademark Office
BOX SEQUENCE, P.O. Box 2327
Arlington, VA 22202

Sir:

This communication and amendment is in response to the Office communication and Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed October 10, 2002. This communication and amendment is being mailed within one month of the mailing date of said notice, making it a timely response. While no fee is believed to be due, the Commissioner is authorized to charge any additional fees, including extension fees or other relief which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. A-70586-1/RFT/RMS/RMK (468488-155)). A copy of the Notice to Comply is enclosed herewith.

Regarding the sequences listed on page 29, lines 1 through 7 of the specification, Applicants respectfully submit that these "sequences" do not represent actual amino acid disclosures and are included in the specification merely as examples to illustrate the difference between contiguous and noncontiguous

amino acid alterations. However, in the event that the Examiner disagrees with this characterization and in order to prevent the Applicant from being considered non-response, Applicant herewith also submits a substitute "Sequence Listing" and the following amendment for the Examiner's consideration.

If the Examiner deems it to be necessary, please amend the application as follows to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures in adherence with rules 37 C.F.R. § 1.821-1.825:

IN THE SPECIFICATION:

Please replace paragraph beginning at page 28, line 34, with the following rewritten paragraph:

—In a preferred embodiment, the amino acid alterations (including substitutions, insertions and deletions) are non-contiguous. By noncontiguous herein is meant that the inserted mutations are not completely continuous along the peptide backbone. At least one amino acid must remain unchanged between two changed amino acids, however, not all changed amino acids need to be noncontiguous. Additionally, regions (areas of contiguous changed or mutated residues) that are noncontiguous are not doubly counted to be noncontiguous with each other if both positions have been already defined as noncontiguous with respect to the same third region. For instance, changing LVLVLVL (SEQ ID NO:8) to LPLPLVL (SEQ ID NO:9) would result in a single noncontiguous change of two amino acids, while LVLVLVL (SEQ ID NO:8) to LPLPLPL (SEQ ID NO:10) would result in two noncontiguous changes (the left P and right P each being noncontiguous with the center P, while the left and right P are also noncontiguous with each other they have both already been counted in a noncontiguous sequence with respect to the center P.) Likewise, LVLVLVL (SEQ ID NO:8) to LPPPLVL (SEQ ID NO:11) is a contiguous change and LVLVLVL (SEQ ID NO:8) to LPPVLPP (SEQ ID NO:12) is a single noncontiguous change. However, LVLVLVL (SEQ ID NO:8) to PPLPPVP (SEQ ID NO:13) would be counted as two noncontiguous changes.—